` Comparison: NVS vs AMGN - Alpha Spread

NVS
vs
AMGN

Over the past 12 months, NVS has significantly outperformed AMGN, delivering a return of +53% compared to the AMGN's +24% growth.

Start AI Comparison

Smart Verdict
AI-Powered

Not Sure Which Stock Wins?
Let AI Decide.
NVS
AMGN
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Smart Verdict is Ready!
See Who Stands Out.
All the numbers, charts, and metrics summarized into one smart verdict.
Stocks Compared:
Show Comparison Results
Summarizing...
We need a little more time to summarize the results

Valuation Comparison

NVS Intrinsic Value
HIDDEN
Show
AMGN Intrinsic Value
HIDDEN
Show
Company Last Price Intrinsic Value DCF Value Relative Value Wall St Target
Novartis AG
NYSE:NVS
169.22 USD
Amgen Inc
NASDAQ:AMGN
386.72 USD
No Stocks Selected

Compare the stock's valuation with its competitors.

Select Stocks to Compare
Valuation Scenario:
Bear Case
Base Case
Bull Case

Growth Comparison

Growth Over Time
NVS, AMGN

NVS
AMGN
Add Stock
Revenue
www.alphaspread.com
No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare
Company LTM Historical Growth Growth Streak % Positive Years Max Drawdown Volatility Forecasted Growth
3 Years 5 Years 10 Years 1 Year 3 Years
Novartis AG
Revenue
Amgen Inc
Revenue

All metrics are calculated based on data from the last 10 years.

No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare

Profitability Comparison

Free Cash Flow
NVS, AMGN

NVS
AMGN
Add Stock
Free Cash Flow
www.alphaspread.com
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
Company LTM Average Historical Growth FCF Margin Conversion
3 Years 5 Years 3 Years 5 Years 10 Years
Novartis AG
NYSE:NVS
Amgen Inc
NASDAQ:AMGN
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
What is Free Cash Flow?

Gross Margin

NVS
75.8%
AMGN
82.5%
LTM 3Y Avg 5Y Avg 10Y Avg
Novartis AG
Amgen Inc

Operating Margin

NVS
33.2%
AMGN
44.1%
LTM 3Y Avg 5Y Avg 10Y Avg
Novartis AG
Amgen Inc

Net Margin

NVS
24.8%
AMGN
21%
LTM 3Y Avg 5Y Avg 10Y Avg
Novartis AG
Amgen Inc

FCF Margin

NVS
27.1%
AMGN
22%
LTM 3Y Avg 5Y Avg 10Y Avg
Novartis AG
Amgen Inc

ROE

NVS
31%
AMGN
106.1%
LTM 3Y Avg 5Y Avg 10Y Avg
Novartis AG
Amgen Inc

ROA

NVS
13.1%
AMGN
8.5%
LTM 3Y Avg 5Y Avg 10Y Avg
Novartis AG
Amgen Inc

ROIC

NVS
17.8%
AMGN
20.1%
LTM 3Y Avg 5Y Avg 10Y Avg
Novartis AG
Amgen Inc

ROCE

NVS
23.8%
AMGN
24.2%
LTM 3Y Avg 5Y Avg 10Y Avg
Novartis AG
Amgen Inc

Solvency Comparison

No Stocks Selected

Compare company's equity waterfall with its competitors.

Select Stocks to Compare
Balance Sheet Comparison
No Stocks Selected

Compare company's balance sheet with its competitors.

Select Stocks to Compare

Stocks Performance

Stocks Performance
NVS, AMGN

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
NVS, AMGN

Performance Gap Between NVS and AMGN
HIDDEN
Show

Performance By Year
NVS, AMGN

Loading
NVS
AMGN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Not Sure Which Stock Wins?
Let AI Decide
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Compare NVS to other stocks
JNJ
Johnson & Johnson
More expensive
vs NVS
ROG
Roche Holding AG
Cheaper
vs NVS
MRK
Merck & Co Inc
Cheaper
vs NVS
BMY
Bristol-Myers Squibb Co
Cheaper
vs NVS
Unlock Full Access to Alpha Spread
Create Free Account
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett